news
Low-Dose Aripiprazole Reverses Post-COVID Hypersomnia in New Case Series
A Frontiers in Neuroscience case series tracked ten patients battling severe hypersomnia and circadian phase delays after COVID-19 infection or vaccination. Treating them with micro-doses of aripiprazole averaging 1.4 mg restored normal wakefulness across the group. The protocol targets post-viral neuroinflammation when standard sleep hygiene fails to work.
A Frontiers in Neuroscience case series tracked ten patients battling severe hypersomnia and circadian phase delays after COVID-19 infection or vaccination. Treating them with micro-doses of aripiprazole averaging 1.4 mg restored normal wakefulness across the group. The protocol targets post-viral neuroinflammation when standard sleep hygiene fails to work.
The architecture take
I spent two years assuming post-viral fatigue was just mitochondrial burnout until a neurologist pointed out dopamine receptor dysregulation. That changed how I track recovery after an illness. Long Covid discussions usually fixate on insomnia or brain fog, but sleeping fourteen hours a day and waking up exhausted is just as brutal. Low-dose aripiprazole sits around 1.4 milligrams here (about a tenth of the standard psychiatric dose). At micro-amounts, the compound acts as a partial dopamine agonist and dampens neuroinflammation in the microglia instead of shutting down receptors. I used to be suspicious of repurposing antipsychotics for stubborn post-viral fatigue. I was dead wrong. When systemic inflammation crosses the blood-brain barrier, standard sleep hygiene won't reset circadian signaling. Ten patients is a tiny series, but chronic fatigue clinics have quietly tested this protocol for months. Watch functional neurologists pick this up next.